Methotrexate Accord Healthcare (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folic acid into its active form. This interruption hampers the synthesis of DNA building blocks, especially in rapidly dividing cells such as immune cells and malignant tumor cells, leading to reduced inflammation and tumor progression.

The dose of Methotrexate Accord Healthcare is individualized based on the specific indication, patient characteristics, and clinical response. The prescribing physician determines the appropriate amount, frequency, and route of administration, and dose adjustments are made according to therapeutic monitoring and safety assessments.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnant women due to a high risk of fetal toxicity and birth defects. It is also not recommended for breastfeeding mothers because it can be excreted in breast milk and may harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing a quotation, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Methotrexate is a conventional disease‑modifying antirheumatic drug (DMARD) and is often the first‑line therapy for rheumatoid arthritis. Compared with biologic agents, it is less expensive and administered orally or by injection, but may require more frequent monitoring for toxicity. Biologics target specific cytokines and may be used when methotrexate alone is insufficient.

Methotrexate Accord Healthcare should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct light. Do not freeze. Ensure that the container remains sealed until use to maintain stability and potency.

Methotrexate can be given via intra‑arterial, intramuscular, or intrathecal injection, depending on the clinical indication and prescribing physician’s recommendation. The route, volume, and infusion rate are determined by the treatment protocol and the patient’s condition.

The most serious risks include severe liver toxicity, pulmonary fibrosis, profound bone‑marrow suppression leading to pancytopenia, life‑threatening infections, acute renal failure, and severe hypersensitivity reactions such as anaphylaxis. Patients should be monitored regularly for early signs of these complications.

Methotrexate is contraindicated in pregnant women, individuals with severe hepatic or renal impairment, patients with active infections, and those with known hypersensitivity to methotrexate or any of its excipients. Caution is also advised for patients with pre‑existing blood disorders or pulmonary disease.